The Oncology Institute Inc Stock Price, News & Analysis

The Oncology Institute, Inc. (NASDAQ: TOI) reported Q1 2022 revenue of $55 million, a 14% increase year-over-year, driven by expansion into new markets and value-based partnerships. Patient Services revenue rose 18.3% to $35 million. Gross profit increased by 20.8% to $12 million, supported by improved cost management. However, SG&A expenses surged to $30 million, up from $11 million, impacting adjusted EBITDA, which stood at $(5) million. TOI maintains its 2022 revenue guidance of $270 to $310 million, reflecting a growth of 33% to 53% over 2021.

The Oncology Institute of Hope and Innovation (TOI) has acquired Women’s Cancer Care, expanding its services into California’s Central Valley. This clinic, established in 2001, is the only facility between San Francisco and Los Angeles specializing in breast and gynecologic oncology. The partnership aims to enhance medical resources and provide advanced care solutions to women in the region. TOI now employs over 80 clinicians and expands its presence with a team of more than 30 in Fresno, enhancing its commitment to value-based cancer care.

The Oncology Institute (TOI) will announce its Q1 2022 financial results on May 11, 2022, after market close, followed by a conference call at 5:00 p.m. ET. Investors can access the call by phone or via a webcast on TOI's Investor Relations website. TOI, established in 2007, focuses on value-based cancer care, serving approximately 1.6 million patients with a team of over 80 clinicians across 50 locations. For more details about the upcoming earnings report and the company's services, visit their official website.

The Oncology Institute of Hope and Innovation (NASDAQ: TOI) announced substantial achievements in the latest Oncology Care Model (OCM) performance period, saving Medicare nearly $9.5M since 2016 and exceeding target savings by $5.3M. The value-based oncology group showcased above-average quality performance, equating to savings of nearly $4,000 per patient episode. With over 80 employed clinicians and expanding services, TOI emphasizes better oncological outcomes while reducing costs for cancer patients across the U.S.

The Oncology Institute of Hope and Innovation (TOI) has appointed Mihir Shah as its new chief financial officer, effective immediately. With 15 years of experience in healthcare finance, Shah has previously served in CFO roles at organizations like Commonwealth Care Alliance and Apollo Medical Holdings. He will oversee critical functions such as Accounting, Finance, and Investor Relations, aiding TOI's strategic growth. Shah takes over from Scott Dalgleish, who will assist during the transition. TOI aims to enhance oncology care through its extensive services, benefiting around 1.6 million patients.

The Oncology Institute of Hope and Innovation (TOI) has expanded its presence in Southern California by opening a new clinic in Culver City on March 7, 2022, and enhancing its Riverside location on March 14, 2022. These expansions aim to improve access to quality oncology care. The Culver City clinic provides comprehensive medical services while the Riverside clinic tripled its infusion space to accommodate a growing patient population. TOI's commitment to advancing cancer care includes a strong emphasis on clinical trials and outpatient services, benefiting both patients and clinicians.

The Oncology Institute (NASDAQ: TOI) reported record revenue of $203 million for 2021, reflecting an 8.3% increase year-over-year.

For Q4, revenue reached $52 million, a 6.8% increase, despite a net loss of $10 million and significant SG&A expenses of $48 million due to growth investments.

Looking ahead to 2022, TOI anticipates revenue of $270 million to $310 million and projects managing between 1.75 million to 2.0 million lives under value-based contracts.

CERRITOS, Calif., March 8, 2022 – The Oncology Institute of Hope and Innovation (NASDAQ: TOI) announced that CEO Brad Hively will participate in the Jefferies Value-Based Healthcare Summit in Miami on March 14 at 1:40 pm EST. Hively has over 20 years of healthcare experience, transforming TOI into a leading oncology provider with over 50 clinics nationwide. The institute offers innovative, value-based cancer care to approximately 1.6 million patients. Investors can access a webcast of the event on the company’s website.

The Oncology Institute of Hope and Innovation (NASDAQ: TOI) has announced the promotions of Dr. Daniel Virnich to President and Dr. Matt Miller to Chief Operating Officer, effective March 15, 2022. These changes are part of a response to TOI's rapid growth. Dr. Virnich, who joined in 2020, will oversee various functions including Operations and Compliance, while Dr. Miller will manage all field and central operations nationally. Both leaders have previously driven tangible improvements in operational efficiency and patient satisfaction, positioning TOI for continued development in specialized oncology care.